Sutro Biopharma (NASDAQ:STRO) Rating Increased to Strong-Buy at Truist Financial

Truist Financial upgraded shares of Sutro Biopharma (NASDAQ:STRO) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

Several other brokerages have also issued reports on STRO. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $8.00 to $27.00 in a research note on Tuesday. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective on the stock in a research note on Tuesday, January 20th. Finally, HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $10.00 to $28.00 in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Sutro Biopharma has an average rating of “Moderate Buy” and a consensus price target of $37.29.

Sutro Biopharma Stock Down 0.3%

Sutro Biopharma stock opened at $23.50 on Wednesday. The business’s 50-day simple moving average is $18.61 and its 200 day simple moving average is $12.76. The stock has a market cap of $199.99 million, a price-to-earnings ratio of -0.90 and a beta of 1.47. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors have recently modified their holdings of the stock. Velan Capital Investment Management LP increased its stake in shares of Sutro Biopharma by 2.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock valued at $2,709,000 after acquiring an additional 60,000 shares during the last quarter. UBS Group AG boosted its stake in Sutro Biopharma by 14.0% during the 3rd quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock worth $1,602,000 after acquiring an additional 226,955 shares during the last quarter. AQR Capital Management LLC boosted its stake in Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after acquiring an additional 1,206,330 shares during the last quarter. Jane Street Group LLC acquired a new position in Sutro Biopharma during the second quarter valued at approximately $492,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Sutro Biopharma in the third quarter valued at approximately $387,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.